Chronic lymphocytic leukemia is a monoclonal proliferative disorder of morphologically mature but functionally impaired B lymphocytes and makes up approximately 30% of all leukemias. The aim of this study was to determine the impact of clinical and biological risk factors on the type of response, the length of progression-free survival and overall survival of patients as well as the assessment of the type and severity of side effects associated with the administered treatment regimen (FCR). Laboratory test results and clinical data of 100 patients with CLL treated in the Department of Hematology in 2008-2014 were analyzed. The results show high efficacy of treatment with the FCR protocol, at 12 months following treatment more than half of the patients (CR = 56%) obtained complete remission. IgVH mutation status and stage of the disease were shown to have independent prognostic value for achievement of complete remission as confirmed in multivariate analysis. The presence of 17p deletion, mutation status of IgVH and high level of MRD were factors of independent prognostic value for progression-free survival. Shortened overall survival was influenced by the presence of the deletion of chromosome 17p, lack of IgVH mutation, the presence of the gene segment V1-69 IgVH, expression of ZAP-70 kinase ≥20% and the level of β2-microglobulin ≥ 3.5 mg/l; deletion of 17p, lack of mutation I ; gVH, elevated β2-microglobulin, and early relapse and showed independent prognostic value. The analysis showed that the applied treatment regimen FCR induced hematological toxicity: granulocytes (Grade 3-4 neutropenia occurred in 70 patients).
Mar 16, 2023
Jun 19, 2015
6
0
http://dl.cm-uj.krakow.pl:8080/publication/3999
Edition name | Date |
---|---|
ZB-122888 | Mar 16, 2023 |
Piotrowska, Magdalena
Ogórka, Tomasz